ANTAGONISTIC ACTION OF AA-2414 ON THROMBOXANE-A2 PROSTAGLANDIN ENDOPEROXIDE RECEPTOR IN PLATELETS AND BLOOD-VESSELS

被引:19
作者
IMURA, Y
TERASHITA, Z
SHIBOUTA, Y
INADA, Y
NISHIKAWA, K
机构
[1] Biology Research Laboratories, Research and Development Division, Takeda Chemical Industries, Ltd., Osaka 532, Juso, Yodogawa-ku
关键词
D O I
10.1254/jjp.52.35
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AA-241 4, (±)-7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-antisecretory acid, inhibited the aggregation of guinea pig platelets induced by a prostaglandin endoperoxide (PGH2) analogue, U-44069 and the specific binding of another analogue, [3H]U-46619 to washed guinea pig platelets with IC50 values of 3.1×10-7+ and 8.2×10-9 M, respectively. AA-2414 competitively inhibited the contraction of rabbit aorta and pig coronary arteries induced by U-44069 with pA2 values of 8.3 and 9.0, respectively. AA-2414 also inhibited the contraction of rabbit aorta induced by PGF2α (pA2:7.8) and the contraction of pig coronary arteries induced by PGF2α, PGD2 and 9α, 11β-PGF2 with pA2 values of 7.8, 8.6 and 7.8, respectively. But, AA-2414 had no effect on the antiaggregatory effect of PGD2 on the aggregation of guinea pig platelets. In experiments with guinea pigs ex vivo, AA-2414 (0.1-1 mg/kg, p.o.) dose-dependently inhibited the platelet aggregation induced by U-44069; the inhibition at a dose of 1 mg/kg was 100% at 1 hr and was 89% even at 24 hr after the administration. The thromboxane (TX) A2/PGH2 receptor antagonistic action of AA-2414 was stereospecific. These results show that AA-2414 is a potent, orally active and long acting TXA2/PGH2 receptor antagonist. In addition, AA-2414 has PGF2α, PGD2 and 9α, 11β-PGF2 antagonistic effects. © 1990, The Japanese Pharmacological Society. All rights reserved.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 23 条
[1]   SOME QUANTITATIVE USES OF DRUG ANTAGONISTS [J].
ARUNLAKSHANA, O ;
SCHILD, HO .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1959, 14 (01) :48-58
[2]   A NOVEL ANTI-ASTHMATIC QUINONE DERIVATIVE, AA-2414 WITH A POTENT ANTAGONISTIC ACTIVITY AGAINST A VARIETY OF SPASMOGENIC PROSTANOIDS [J].
ASHIDA, Y ;
MATSUMOTO, T ;
KURIKI, H ;
SHIRAISHI, M ;
KATO, K ;
TERAO, S .
PROSTAGLANDINS, 1989, 38 (01) :91-112
[3]  
BEST LC, 1980, THROMB HAEMOSTASIS, V43, P38
[4]   AGGREGATION OF BLOOD PLATELETS BY ADENOSINE DIPHOSPHATE AND ITS REVERSAL [J].
BORN, GVR .
NATURE, 1962, 194 (4832) :927-&
[5]   THE PROSTACYCLIN-THROMBOXANE-A2 BALANCE - PATHOPHYSIOLOGICAL AND THERAPEUTIC IMPLICATIONS [J].
BUNTING, S ;
MONCADA, S ;
VANE, JR .
BRITISH MEDICAL BULLETIN, 1983, 39 (03) :271-276
[6]  
FINNEY DJ, 1964, STATISTICAL METHODS, P27
[7]   THROMBOXANES - NEW GROUP OF BIOLOGICALLY-ACTIVE COMPOUNDS DERIVED FROM PROSTAGLANDIN ENDOPEROXIDES [J].
HAMBERG, M ;
SVENSSON, J ;
SAMUELSSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (08) :2994-2998
[8]  
IMAMOTO T, 1986, J CARDIOVASC PHARM, V8, P832
[9]   THE THROMBOXANE-A2 PROSTAGLANDIN ENDOPEROXIDE RECEPTOR ANTAGONIST ACTIVITY OF CV-4151, A THROMBOXANE-A2 SYNTHETASE INHIBITOR [J].
IMURA, Y ;
TERASHITA, Z ;
SHIBOUTA, Y ;
NISHIKAWA, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1988, 147 (03) :359-365
[10]   CHARACTERIZATION OF U46619 BINDING IN UNACTIVATED, INTACT HUMAN-PLATELETS AND DETERMINATION OF BINDING-SITE AFFINITIES OF 4 TXA2/PGH2 RECEPTOR ANTAGONISTS (13-APA, BM 13.177, ONO 3708 AND SQ 29,548) [J].
KATTELMAN, EJ ;
VENTON, DL ;
LEBRETON, GC .
THROMBOSIS RESEARCH, 1986, 41 (04) :471-481